CELLINK Q5 2020 Results and MatTek Acquisition
CELLINK
LIFE SCIENCES
1
2
3
Through the strategic acquisition of MatTek,
the CELLINK Group will achieve the following:
Provide alternative testing models which enables the reduction, and in some cases elimination,
of animal testing. These solutions allow researchers to gather better data through more
physiologically relevant models and thus make better predictions.
Several strong synergies by combining cutting-edge bioprinting technology and modular
large-scale robotic flows with 3D reconstructed, human-derived tissue models.
Acquisition is in line with CELLINK's commercial, bioconvergence strategy, complementing
CELLINK's product offering and brings the Group closer to the patients through cutting edge
products used in clinical and pre-clinical studies.View entire presentation